Trial Outcomes & Findings for A Prospective, Multi-center, Observational Study of the Use of Permacol™ Collagen Paste to Treat Anorectal Fistulas (NCT NCT01624350)

NCT ID: NCT01624350

Last Updated: 2016-11-30

Results Overview

Clinical assessment of fistula healing as defined by 1) no discharge from the fistula and 2) the external opening has closed.

Recruitment status

COMPLETED

Target enrollment

100 participants

Primary outcome timeframe

6 months

Results posted on

2016-11-30

Participant Flow

Participant milestones

Participant milestones
Measure
Permacol Collagen Paste
Overall Study
STARTED
100
Overall Study
COMPLETED
75
Overall Study
NOT COMPLETED
25

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

A Prospective, Multi-center, Observational Study of the Use of Permacol™ Collagen Paste to Treat Anorectal Fistulas

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Permacol Collagen Paste
n=100 Participants
Age, Continuous
45.9 years
STANDARD_DEVIATION 13.68 • n=5 Participants
Gender
Female
30 Participants
n=5 Participants
Gender
Male
70 Participants
n=5 Participants
Region of Enrollment
Denmark
15 participants
n=5 Participants
Region of Enrollment
United Kingdom
52 participants
n=5 Participants
Region of Enrollment
Italy
33 participants
n=5 Participants

PRIMARY outcome

Timeframe: 6 months

Population: Number of participants analyzed includes patients who had their assessment performed and the final assessment of patients who exited from the study early.

Clinical assessment of fistula healing as defined by 1) no discharge from the fistula and 2) the external opening has closed.

Outcome measures

Outcome measures
Measure
Permacol Collagen Paste
n=97 Participants
Permacol Collagen Paste - 12 Month Follow up
Permacol Collagen Paste - 6 Month Post-op
Permacol Collagen Paste - 12 Month Post-op
Permacol Collagen Paste - 12 Month Post-op
Fistula Healing in Patients at 6 Months Following Surgery
Yes
56.7 percentage of participants
Fistula Healing in Patients at 6 Months Following Surgery
No
43.3 percentage of participants

SECONDARY outcome

Timeframe: 3 months and 12 months

Population: Number of participants analyzed includes patients who had their assessment performed and the final assessment of patients who exited from the study early.

Clinical assessment of fistula healing as defined by 1) no discharge from the fistula and 2) the external opening has closed.

Outcome measures

Outcome measures
Measure
Permacol Collagen Paste
n=94 Participants
Permacol Collagen Paste - 12 Month Follow up
n=99 Participants
Permacol Collagen Paste - 6 Month Post-op
Permacol Collagen Paste - 12 Month Post-op
Permacol Collagen Paste - 12 Month Post-op
Fistula Healing in Patients at 3 and 12 Months Following Surgery
Yes
53.2 percentage of patients
Interval 42.6 to 63.6
53.5 percentage of patients
Interval 43.2 to 63.6
Fistula Healing in Patients at 3 and 12 Months Following Surgery
No
46.8 percentage of patients
Interval 42.6 to 63.6
46.5 percentage of patients
Interval 43.2 to 63.6

SECONDARY outcome

Timeframe: Baseline, and 3 months, 6 months and 12 months post op

Population: Number analyzed include participants who completed questionnaire.

Quality of Life by EQ-5D questionnaire is a standardized measure of health status. It is a 25-item questionnaire that measures quality of life of patients pre and post surgery in the following categories: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each category has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems.

Outcome measures

Outcome measures
Measure
Permacol Collagen Paste
n=97 Participants
Permacol Collagen Paste - 12 Month Follow up
n=88 Participants
Permacol Collagen Paste - 6 Month Post-op
n=79 Participants
Permacol Collagen Paste - 12 Month Post-op
n=74 Participants
Permacol Collagen Paste - 12 Month Post-op
Participant Response to Quality of Life EQ-5D Questionnaire
I have no problems in walking about
74 participants
77 participants
76 participants
72 participants
Participant Response to Quality of Life EQ-5D Questionnaire
I have moderate problems in walking about
10 participants
3 participants
0 participants
1 participants
Participant Response to Quality of Life EQ-5D Questionnaire
I have severe problems in walking about
0 participants
1 participants
0 participants
1 participants
Participant Response to Quality of Life EQ-5D Questionnaire
I am unable to walk about
0 participants
0 participants
1 participants
0 participants
Participant Response to Quality of Life EQ-5D Questionnaire
I have no problems washing or dressing myself
87 participants
84 participants
78 participants
72 participants
Participant Response to Quality of Life EQ-5D Questionnaire
I have slight problems washing or dressing myself
7 participants
3 participants
0 participants
1 participants
Participant Response to Quality of Life EQ-5D Questionnaire
I have moderate problems washing or dressing mysel
1 participants
1 participants
1 participants
1 participants
Participant Response to Quality of Life EQ-5D Questionnaire
I have severe problems washing or dressing myself
1 participants
0 participants
0 participants
0 participants
Participant Response to Quality of Life EQ-5D Questionnaire
I am unable to wash or dress myself
1 participants
0 participants
0 participants
0 participants
Participant Response to Quality of Life EQ-5D Questionnaire
I have slight problems doing my usual activities
13 participants
12 participants
6 participants
9 participants
Participant Response to Quality of Life EQ-5D Questionnaire
I have moderate problems doing my usual activities
8 participants
6 participants
0 participants
1 participants
Participant Response to Quality of Life EQ-5D Questionnaire
I have no pain or discomfort
38 participants
46 participants
52 participants
49 participants
Participant Response to Quality of Life EQ-5D Questionnaire
I have slight pain or discomfort
44 participants
31 participants
22 participants
20 participants
Participant Response to Quality of Life EQ-5D Questionnaire
I have severe pain or discomfort
2 participants
1 participants
0 participants
1 participants
Participant Response to Quality of Life EQ-5D Questionnaire
I have extreme pain or discomfort
0 participants
0 participants
1 participants
1 participants
Participant Response to Quality of Life EQ-5D Questionnaire
I am not anxious or depressed
63 participants
69 participants
67 participants
56 participants
Participant Response to Quality of Life EQ-5D Questionnaire
I am severely anxious or depressed
1 participants
0 participants
0 participants
0 participants
Participant Response to Quality of Life EQ-5D Questionnaire
I have slight problems in walking about
13 participants
7 participants
2 participants
0 participants
Participant Response to Quality of Life EQ-5D Questionnaire
I have no problems doing my usual activities
72 participants
69 participants
72 participants
63 participants
Participant Response to Quality of Life EQ-5D Questionnaire
I have severe problems doing my usual activities
4 participants
1 participants
1 participants
1 participants
Participant Response to Quality of Life EQ-5D Questionnaire
I have moderate pain or discomfort
13 participants
10 participants
4 participants
3 participants
Participant Response to Quality of Life EQ-5D Questionnaire
I am slightly anxious or depressed
24 participants
13 participants
9 participants
13 participants
Participant Response to Quality of Life EQ-5D Questionnaire
I am moderately anxious or depressed
8 participants
6 participants
2 participants
4 participants
Participant Response to Quality of Life EQ-5D Questionnaire
I am extremely anxious or depressed
1 participants
0 participants
1 participants
1 participants

SECONDARY outcome

Timeframe: 3 months, 6 months and 12 months

Population: The CCF-FI score was calculated if a score was ticked for each of the five types of incontinence. If a patient had a type of incontinence with a missing score, then the CCF-FI score was not calculated. Change = Value and Month X - Value at Baseline.

Fecal Incontinence change from baseline as measured by CCF-FI questionnaire. This questionnaire is a summed score of 5 individual parameters (frequency of incontinence to gas, liquid solid, of need to wear pad, and of lifestyle changes) It is measured from a patient-completed questionnaire with each parameter given a score from 0 to 4, with 0 indicating its absence and 4 indicating daily presence. These values are added to give a total score ranging from 0 to 20 (0 indicating perfect control, 10-15 indicating moderate incontinence, and greater than 15 indicating severe incontinence.

Outcome measures

Outcome measures
Measure
Permacol Collagen Paste
n=85 Participants
Permacol Collagen Paste - 12 Month Follow up
n=76 Participants
Permacol Collagen Paste - 6 Month Post-op
n=70 Participants
Permacol Collagen Paste - 12 Month Post-op
Permacol Collagen Paste - 12 Month Post-op
Fecal Incontinence
-1.0 units on a scale
Standard Deviation 3.75
-1.1 units on a scale
Standard Deviation 3.58
-0.9 units on a scale
Standard Deviation 3.75

SECONDARY outcome

Timeframe: Between the first and last visits

Population: Number of participants completed a satisfaction questionnaire at least twice.

Patient satisfaction questionnaire included questions regarding fecal continence and overall satisfaction with the operation.

Outcome measures

Outcome measures
Measure
Permacol Collagen Paste
n=85 Participants
Permacol Collagen Paste - 12 Month Follow up
n=85 Participants
Permacol Collagen Paste - 6 Month Post-op
Permacol Collagen Paste - 12 Month Post-op
Permacol Collagen Paste - 12 Month Post-op
Patient Satisfaction Between the First and Last Post-operative Visit
Very Satisfied
37 Participants
44 Participants
Patient Satisfaction Between the First and Last Post-operative Visit
Satisfied
39 Participants
18 Participants
Patient Satisfaction Between the First and Last Post-operative Visit
Dissatisfied
8 Participants
18 Participants
Patient Satisfaction Between the First and Last Post-operative Visit
Very Dissatisfied
1 Participants
5 Participants

SECONDARY outcome

Timeframe: Baseline, 1 month, 3 months, 6 months and 12 months

Population: Participants include number of patients who completed questionnaire

Pain by VAS (Visual Analog Scale) VAS is a 10-point scale with 0 being no pain and 10 being the most pain.

Outcome measures

Outcome measures
Measure
Permacol Collagen Paste
n=98 Participants
Permacol Collagen Paste - 12 Month Follow up
n=98 Participants
Permacol Collagen Paste - 6 Month Post-op
n=88 Participants
Permacol Collagen Paste - 12 Month Post-op
n=79 Participants
Permacol Collagen Paste - 12 Month Post-op
n=74 Participants
Pain
Severe Pain (7-10)
8 Participants
1 Participants
1 Participants
2 Participants
3 Participants
Pain
No Pain (0)
29 Participants
45 Participants
47 Participants
47 Participants
53 Participants
Pain
Mild Pain (1-3)
44 Participants
41 Participants
33 Participants
26 Participants
13 Participants
Pain
Moderate Pain (4-6)
17 Participants
11 Participants
7 Participants
4 Participants
5 Participants

Adverse Events

Permacol Collagen Paste

Serious events: 6 serious events
Other events: 29 other events
Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure
Permacol Collagen Paste
n=100 participants at risk
Gastrointestinal disorders
Anal fistula
1.0%
1/100 • Number of events 1
Infections and infestations
Anal Abscess
2.0%
2/100
Nervous system disorders
Complex regional pain syndrome
1.0%
1/100
Pregnancy, puerperium and perinatal conditions
Pregnancy
1.0%
1/100
Injury, poisoning and procedural complications
Procedural pain
1.0%
1/100

Other adverse events

Other adverse events
Measure
Permacol Collagen Paste
n=100 participants at risk
Cardiac disorders
Tachycardia
1.0%
1/100
Ear and labyrinth disorders
Ear Pain
1.0%
1/100
Gastrointestinal disorders
Anal Fissure
1.0%
1/100
Gastrointestinal disorders
Anal Fistula
2.0%
2/100
Gastrointestinal disorders
Constipation
1.0%
1/100
Gastrointestinal disorders
Dyspepsia
1.0%
1/100
Gastrointestinal disorders
Haemorrhoids
2.0%
2/100
Gastrointestinal disorders
Proctalgia
6.0%
6/100
Gastrointestinal disorders
Rectal Haemorrhage
1.0%
1/100
General disorders
Pain
1.0%
1/100
Infections and infestations
Anal abscess
4.0%
4/100
Infections and infestations
Anal fistula infection
2.0%
2/100
Infections and infestations
Infected fistula
1.0%
1/100
Infections and infestations
Pilonidal cyst
1.0%
1/100
Infections and infestations
pneumonia
1.0%
1/100
Infections and infestations
postoperative wound infection
3.0%
3/100
Infections and infestations
purulent discharge
1.0%
1/100
Injury, poisoning and procedural complications
facial bones fracture
1.0%
1/100
Injury, poisoning and procedural complications
procedural pain
3.0%
3/100
Injury, poisoning and procedural complications
Seroma
2.0%
2/100
Nervous system disorders
Complex regional pain syndrome
1.0%
1/100
Pregnancy, puerperium and perinatal conditions
pregnancy
1.0%
1/100
Reproductive system and breast disorders
breast mass
1.0%
1/100
Respiratory, thoracic and mediastinal disorders
Asthma
1.0%
1/100
Skin and subcutaneous tissue disorders
decubitus ulcer
1.0%
1/100
Skin and subcutaneous tissue disorders
eczema
1.0%
1/100
Skin and subcutaneous tissue disorders
hypertrophic scar
1.0%
1/100
Vascular disorders
haemorrhage
1.0%
1/100

Additional Information

Medtronic (Sponsor)

Medtronic

Phone: 508.452.4095

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place